Patents Assigned to Pelagos Pharmaceuticals, Inc.
  • REV-ERB AGONISTS
    Publication number: 20240002380
    Abstract: Disclosed are compounds that regulate REV-ERB nuclear receptors that would be useful for treatment of various diseases. These compounds may be used in therapeutic applications such as in the treatment of neurodegenerative disease such as anxiety disorder, autoimmune diseases or disorders, or muscular disorders such as sarcopenia.
    Type: Application
    Filed: April 13, 2023
    Publication date: January 4, 2024
    Applicants: Saint Louis University, Pelagos Pharmaceuticals, Inc.
    Inventors: John K. Walker, Thomas Patrick Burris, Sadichha Sitaula, Arindam Chatterjee, Napoleon Clement D'Cunha, Eric Jon Jacobsen, James Robert Blinn